Not 100% comparing apples with apples, but it does appear ciltacabtagene autoleucel (cilta-cel), will over time become 1st line treatment, where its currently on 3rd line treatment.
https://www.cancernetwork.com/view/adjusted-comparison-of-cilta-cel-vs-standard-regimens-reveals-favorable-outcomes-in-triple-class-exposed-multiple-myeloma
Ann: Expanded Heart Protection Discovery for Zantrene, page-257
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.52 |
Change
0.030(2.01%) |
Mkt cap ! $254.2M | |||
| Open | High | Low | Value | Volume |
| $1.51 | $1.53 | $1.48 | $141.7K | 94.55K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 427 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.52 | 2999 | 2 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.51 |
Change
0.030 ( 0.85 %) |
||||
| Open | High | Low | Volume | ||
| $1.52 | $1.53 | $1.48 | 13236 | ||
| Last updated 15.53pm 21/05/2024 ? | |||||
| RAC (ASX) Chart |